Validant snags DataRevive

Validant acquires DataRevive, a regulatory strategy and consulting business

DDNews Staff
SAN FRANCISCO—Validant, a leading transatlantic quality, compliance and regulatory consulting group, has acquired DataRevive LLC, a regulatory strategy and consultancy firm that focuses on supporting pharma and biotech and navigating the regulatory approval pathway for global clients in the U.S. market.
 
“We’re delighted to announce our acquisition of DataRevive and are excited about the combination with Validant,” said Brian Burns, CEO of Validant, commenting on the announcement. “The DataRevive team brings a wealth of knowledge and new expertise into the business, complementing the Validant team. Together, we are in a better position to support our existing and new clients manage their regulatory and quality needs.”
 
Validant blends industry expertise with innovation to create custom solutions for companies on the frontier of health. The company’s network represents the largest assembly of leading engineers, scientists, clinicians and specialists in the field. Validant’s acquisition of DataRevive is part of its international growth strategy through both organic expansion and selective acquisitions. This move follows its partnership with GHO Capital, a leading specialist healthcare investment adviser based in London, in December 2018.
 
The combination of DataRevive and Validant will strengthen and expand the combined group’s service offering across regulatory driven life science consulting and allow both businesses to better serve their clients across the development lifecycle.
 
“Joining forces with Validant will provide new commercial channels to deliver our services to a broader array of global biopharma customers. It will also strengthen our capability to provide world class quality and compliance services to enable our clients to achieve and maintain marketing applications globally. Our team are looking forward to being able to leverage the Validant network and best-in-class operating model to support a broader and growing customer base,” noted Audrey Jia, CEO of DataRevive.
 
Established in 2016 by Jia, DataRevive is constructed around a high-quality partner base with a mixture of ex-FDA and industry employees that bring unique expertise into the business. DataRevive focuses on novel therapeutics and biologics, the fastest growth segments of the market.
 
The acquisition will add a new location in Washington D.C. to complement Validant’s existing footprint in San Francisco, the Research Triangle Park in North Carolina and Cork, Ireland. With many international clients, DataRevive will also broaden the group’s exposure to and expertise in significant new growth markets.

DDNews Staff

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

November 2022 Issue Front Cover

Latest Issue  

• Volume 18 • Issue 11 • November 2022

November 2022

November 2022